{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-282547","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2024-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.868907+00:00","generated_at":"2026-05-29T00:28:41.531367+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"BioAtla updates corporate presentation; no specific details available in excerpt","bullets":["BioAtla furnished an updated corporate presentation on December 20, 2024, for investor meetings.","The presentation title references 'Conditionally Active Biologics' but no clinical or financial data are shown in the provided excerpt.","Without the full presentation content, no material new information can be extracted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-282547","json":"https://secwatch.observer/filing/0001193125-24-282547.json","markdown":"https://secwatch.observer/filing/0001193125-24-282547.md","text":"https://secwatch.observer/filing/0001193125-24-282547.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000119312524282547/0001193125-24-282547-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000119312524282547/d913994d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T00:28:41.531367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}